Browsing by Author "Pairon, Jean-Claude"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    FGFR3 and TP53 Gene Mutations Define Two Distinct Pathways in Urothelial Cell Carcinoma of the Bladder
    (American Association for Cancer Research, 12/01/2003) Bakkar, Ashraf A; Wallerand, Herve; Radvanyi, François; Lahaye, Jean-Baptiste; Pissard, Serge; Lecerf, Laure; Kouyoumdjian, Claude; Abbou, Claude C; Jaurand, Marie-Claude; Pairon, Jean-Claude; Chopin, Dominique K; Diez de Medina, Sixtina Gil
    FGFR3 and TP53 mutations are frequent in superficial papillary and invasive disease, respectively. We used denaturing high-performance liq- uid chromatography and sequencing to screen for FGFR3 and TP53 mutations in 81 newly diagnosed urothelial cell carcinomas. Tumors were classified as follows: 31 pTa, 1 carcinoma in situ, 30 pT1, and 19 pT2-T4. Tumor grades were as follows: 10 G1, 29 G2, and 42 G3. FGFR3 muta- tions were associated with low-stage (P < 0.0001), low-grade (P < 0.008) tumors, whereas TP53 mutations were associated with high-stage (P < 0.003), high-grade (P < 0.02) tumors. Mutations in these two genes were almost mutually exclusive. Our results suggest that FGFR3 and TP53 mutations define separate pathways at initial diagnosis of urothelial cell carcinoma.
  • Thumbnail Image
    Item
    Mutations in TP53 , but not FGFR3 , in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens
    (Oxford University Press, 2005) Wallerand, Hervé; A Bakkar, Ashraf; Gil Diez De Medina, Sixtina; Pairon, Jean-Claude; Ching Yang, Yu; Vordos, Dimitri; Bittard, Hugues; Fauconnet, Sylvie; Kouyoumdjian, Jean-Claude; Claude Jaurand, Marie; Feng Zhang, Zuo; Radvanyi, François; Thiery, Jean-Paul; K Chopin, Dominique
    Smoking is a major risk factor for urothelial cell carcinoma of the bladder (UCC). Mutations in the FGFR3 and TP53 genes have been shown to define two distinct pathways in superficial papillary and invasive UCC disease, respectively. We investigated the relationship between smoking and these mutations by means of denaturing high performance liquid chromatography and sequencing for 110 primary UCC of the bladder. This study included 48 current smokers, 31 ex-smokers and 31 non-smokers. Thirty-five of the tumors were stage pTa, 40 pT1 and 35 ≥pT2. Fourteen of the tumors were grade 1, 37 were grade 2 and 59 grade 3. Smoking was associated with high stage ( P = 0.03) and high grade tumors ( P = 0.006). Twenty-two of the 110 tumors studied harbored TP53 mutations (20%) and 43 harbored FGFR3 mutations (39%). Odds ratios (OR) were higher for TP53 mutations in current smokers [OR, 2.25; 95% confidence interval (95% CI), 0.65–7.75] and ex-smokers (OR, 1.62; 95% CI, 0.41–6.42) than in non-smokers. Double TP53 mutations and the A:T→G:C TP53 mutation pattern was found only in current smokers. Patients with the FGFR3wild-type / TP53mutated genotype had significantly higher levels of tobacco consumption, as measured in pack-years ( P = 0.01). Smoking influenced neither the frequency nor the pattern of FGFR3 mutations. Our results suggest that smoking is associated with invasive and high grade UCCs, at initial presentation, and influenced TP53 or the molecular pathway defined by these mutations. In contrast, FGFR3 mutations are not affected by smoking and probably result from endogenous alterations. These data have potential implications for clinical management and prevention strategies.